首页> 外文期刊>Journal of Pharmaceutical and Biomedical Analysis: An International Journal on All Drug-Related Topics in Pharmaceutical, Biomedical and Clinical Analysis >Optimization and validation of DNA extraction and real-time PCR assay for the quantitative measurement of residual host cell DNA in biopharmaceutical products
【24h】

Optimization and validation of DNA extraction and real-time PCR assay for the quantitative measurement of residual host cell DNA in biopharmaceutical products

机译:DNA提取和实时PCR分析的优化和验证,用于定量测定生物制药产品中残留的宿主细胞DNA

获取原文
获取原文并翻译 | 示例
           

摘要

Host cell DNA contamination occurs during the production of biopharmaceuticals and must be controlled and monitored for the purity and safety of the drug products. A sodium iodide-based DNA extraction and a subsequent real time PCR assay were developed and validated for the quantitative measurement of residual host cell DNA impurity in monoclonal antibody therapeutic products.A sodium iodide-based commercial kit was optimized for the removal of interfering matrices. Several incubation steps from the kit protocol were combined and a neutralization buffer was introduced to protein digestion step to eliminate any precipitation from the detergent. The elimination of the two washing steps significantly reduced assay variability from loss of DNA pellets. The optimized DNA extraction procedure can recover DNA close to 100% for DNA concentrations from 10 to 100,000. pg/mL. Of the published sequences of repetitive interspersed nuclear elements, we identified a nucleotide mismatch from the published CHO probe. Correction of this nucleotide increased DNA amplification by a thousand fold.The optimized assay was further validated for the quantitation of residual CHO DNA according to ICH guidelines with preset assay acceptance criteria. The method met all assay acceptance criteria and was found linear, accurate and precise for the quantitation of residual CHO in the linear range of 10-100,000. pg DNA/mL. LOQ was measured at 10. pg DNA/mL and LOD at 1. pg DNA/mL. No matrix interference to our validated assay was detected from bioreactor harvest, Protein A eluate or eluate from ion exchange columns.
机译:宿主细胞DNA污染发生在生物药物生产过程中,必须控制和监控药物纯度和安全性。开发了基于碘化钠的DNA提取和随后的实时PCR分析,并验证了该方法可用于定量测量单克隆抗体治疗产品中残留的宿主细胞DNA杂质。基于碘化钠的商业试剂盒经过优化,可去除干扰基质。合并试剂盒规程中的几个孵育步骤,并将中和缓冲液引入蛋白质消化步骤,以消除去污剂中的任何沉淀。消除了两个洗涤步骤,大大降低了DNA沉淀物丢失带来的测定变异性。优化的DNA提取程序可从10到100,000的DNA浓度回收接近100%的DNA。 pg / mL。在已发表的重复散布的核元素序列中,我们从已发表的CHO探针中鉴定出核苷酸错配。对该核苷酸的校正使DNA扩增增加了1000倍。根据ICH指南以及预设的检测标准,进一步验证了优化的检测方法可定量残留CHO DNA。该方法满足所有测定的接受标准,并且发现线性,准确和精确,可在10-100,000的线性范围内定量残留CHO。 pg DNA /毫升。 LOQ为10. pg DNA / mL,LOD为1. pg DNA / mL。从生物反应器收获物,蛋白A洗脱液或离子交换柱洗脱液中未检测到对我们验证的测定有基质干扰。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号